-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
AVG-233
![{PARAM:[Name]}({[CAS]})](https://resource.bocsci.com/structure/2151937-80-1.gif)
| Category | Respiratory syncytial Virus (RSV) |
| CAS | 2151937-80-1 |
| Description | AVG-233 is a potent, orally active RNA dependent RNA polymerase (RdRp) inhibitor. AVG-233 prevents initiation of the viral polymerase complex at the promoter. AVG-233 binding site is present in the L1-1749 fragment. AVG-233 has nanomolar activity against both RSV strains and clinical RSV isolates (EC50=0.14-0.31 μM). AVG-233 can be used for research of respiratory syncytial virus (RSV). |
Product Information
| Synonyms | 2151937-80-1|5-((6-Chloropyridin-2-yl)methyl)-1-(4-methoxybenzyl)-4-methyl-2-(pyridin-2-yl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione|SCHEMBL19607757|AVG-233|5-[(6-Chloropyridin-2-yl)methyl]-1-[(4-methoxyphenyl)methyl]-4-methyl-2-pyridin-2-ylpyrazolo[4,3-c]pyridine-3,6-dione |
| Molecular Weight | 487.944 |
| Molecular Formula | C26H22ClN5O3 |
| Canonical SMILES | CC1=C2C(=CC(=O)N1CC3=NC(=CC=C3)Cl)N(N(C2=O)C4=CC=CC=N4)CC5=CC=C(C=C5)OC |
| Purity | 0.9813 |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months -20°C, 1 month (sealed storage, away from moisture) |
| Complexity | 884 |
| Exact Mass | 487.1411173 |
| In Vitro | AVG-233 (1-100 μM) blocks 3'RNA extension elongation but does not interfere with 3'RNA extension by up to three nucleotides after de novo initiation from the promoter or back-priming. AVG-233 (20 μM) reduces virus yield of RSV A2-L19F (EC50=0.31 μM), RSV strain 2-20 (EC50=0.14 μM) and RSV clinical isolate 718 (EC50=0.2 μM). AVG-233 (1.25-40 μM; 0-300 s) suppresses RNA synthesis by the L1-1749 fragment in a dose-dependent manner with an IC50 value of 13.7 μM. |
| In Vivo | AVG-233 (50-100 mg/kg; i.g.; once) decreases lung viral load in the RSV mouse model. AVG-233 (2-20 mg/kg; i.v. and p.o.; once; male CD-1 mice) has good orally bioavailable and the maximum plasma concentration about 2 μM. |
| Target | DNA/RNA Synthesis; RSV |
| XLogP3-AA | 3.5 |